61 related articles for article (PubMed ID: 3537547)
41. Lymphokine-mediated immunotherapy studies in mouse tumor systems.
Papermaster BW; Gilliland CD; McEntire JE; Smith ME; Buchok SJ
Cancer; 1980 Mar; 45(5 Suppl):1248-53. PubMed ID: 7357517
[TBL] [Abstract][Full Text] [Related]
42. Proceedings of the second meeting of the IUIS Lymphokine Standardization Subcommittee. March 5 and 8, 1986, Erlangen, West Germany.
Lymphokine Res; 1986; 5 Suppl 1():S1-192. PubMed ID: 3537546
[No Abstract] [Full Text] [Related]
43. Immunomodulators as local hormones: new insights regarding their clinical utilization.
Bocci V
J Biol Response Mod; 1985 Aug; 4(4):340-52. PubMed ID: 2411878
[No Abstract] [Full Text] [Related]
44. Phase I clinical trial of an MAF-containing lymphoblastoid cell line supernatant.
Reynolds RD; McEntire JE; Rodes ND; Dunn PA; Walter J; Doyle MK; Anson NO; Garcia A; Oxenhandler RW; Khojasteh A
J Biol Response Mod; 1986 Apr; 5(2):129-39. PubMed ID: 3525761
[TBL] [Abstract][Full Text] [Related]
45. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer.
Pulley MS; Nagendran V; Edwards JM; Dumonde DC
Lymphokine Res; 1986; 5 Suppl 1():S157-63. PubMed ID: 3784610
[TBL] [Abstract][Full Text] [Related]
46. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
47. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
48. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
49. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
50. Lymphokine gene therapy for cancer.
Russell SJ
Immunol Today; 1990 Jun; 11(6):196-200. PubMed ID: 2191681
[TBL] [Abstract][Full Text] [Related]
51. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
